New York Recalls Cannabis Products After Lab Issues False Results

New York's Office of Cannabis Management ordered a precautionary recall of multiple adult-use cannabis products last week after determining that Keystone State Testing New York issued unreliable test results over a two-month period.

The recall affects products tested by the Vestal-based laboratory between December 2024 and January 2025. The OCM launched an investigation into the state-licensed testing facility after discovering irregularities in its quality control procedures.

Testing labs serve as critical gatekeepers in regulated cannabis markets, screening products for potency, pesticides, heavy metals, and microbial contaminants before they reach dispensary shelves. When these systems fail, the entire supply chain faces disruption.

The Testing Problem

The OCM has not yet disclosed which specific products are affected by the recall or how many licensed retailers must pull inventory from shelves. The agency also hasn't specified what type of testing failures occurred—whether the lab reported false negatives for contaminants, inflated potency numbers, or failed to detect harmful substances.

Keystone State Testing operates facilities in multiple states. The company's New York location received its state license to test adult-use cannabis products as part of the state's regulatory framework launched in 2022.

New York's adult-use market has faced persistent supply chain challenges since recreational sales began. The state initially struggled with a shortage of licensed testing labs, creating bottlenecks that delayed product launches and limited dispensary inventory. This recall adds another complication for retailers already navigating a competitive market that includes a vast unlicensed sector.

Industry Impact

Licensed dispensaries must now identify and remove affected products while waiting for retesting results. For smaller operators, the financial impact of a recall can be severe—products sitting in quarantine represent tied-up capital and lost revenue during peak sales periods.

The recall also raises questions about New York's laboratory oversight protocols. State regulators typically conduct regular audits of testing facilities, but the two-month window suggests the problems weren't caught immediately through routine monitoring.

Other states have grappled with similar testing scandals. California shut down multiple labs in recent years for falsifying results, while Michigan suspended licenses after discovering labs that routinely passed contaminated products. These incidents have prompted calls for more rigorous proficiency testing and third-party audits of cannabis laboratories.

What Happens Next

The OCM hasn't announced whether Keystone State Testing's license will be suspended or if the lab faces financial penalties. Affected products will need retesting at other state-licensed facilities before they can return to dispensary shelves—a process that typically takes several weeks.

Consumers who purchased products tested by Keystone during the affected period should check with their dispensary for recall information. The OCM is expected to release a detailed list of recalled products and batch numbers in coming days.

The incident underscores the ongoing maturation challenges in New York's cannabis program, which continues balancing rapid market expansion with adequate regulatory oversight. As the state adds more licensed operators, ensuring testing integrity remains a fundamental consumer safety issue.

This article is based on original reporting by ganjapreneur.com.